Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and 
ALS

Chatterjee, M.; Özdemir, S.; Fritz, C.; Möbius, W.; Kleineidam, L.; Mandelkow, E.; Biernat, J.; Doğdu, C.; Peters, O.; Cosma, N.C.; Wang, X.; Schneider, L.-S.; Priller, J.; Spruth, E.; Kühn, A.A.; Krause, P.; Klockgether, T.; Vogt, I.R.; Kimmich, O.; Spottke, A.; Hoffmann, D.C.; Fliessbach, K.; Miklitz, C.; McCormick, C.; Weydt, P.; Falkenburger, B.; Brandt, M.; Guenther, R.; Dinter, E.; Wiltfang, J.; Hansen, N.; Bähr, M.; Zerr, I.; Flöel, A.; Nestor, P.J.; Düzel, E.; Glanz, W.; Incesoy, E.; Bürger, K.; Janowitz, D.; Perneczky, R.; Rauchmann, B.S.; Hopfner, F.; Wagemann, O.; Levin, J.; Teipel, S.; Kilimann, I.; Goerss, D.; Prudlo, J.; Gasser, T.; Brockmann, K.; Mengel, D.; Zimmermann, M.; Synofzik, M.; Wilke, C.; Selma-González, J.; Turon-Sans, J.; Santos-Santos, M.A.; Alcolea, D.; Rubio-Guerra, S.; Fortea, J.; Carbayo, Á.; Lleó, A.; Rojas-García, R.; Illán-Gala, I.; Wagner, M.; Frommann, I.; Roeske, S.; Bertram, L.; Heneka, M.T.; Brosseron, F.; Ramirez, A.; Schmid, M.; Beschorner, R.; Halle, A.; Herms, J.; Neumann, M.; Barthélemy, N.R.; Bateman, R.J.; Rizzu, P.; Heutink, P.; Dols-Icardo, O.; Höglinger, G.; Hermann, A.; Schneider, A.

doi:10.1038/s41591-024-02937-4

アイテム詳細

登録内容を編集ファイル形式で保存

一時保存へ追加

タグ情報を表示リリース履歴を表示詳細要約

公開

学術論文

Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS

MPS-Authors

/persons/resource/persons182306

Möbius, W.
Department of Neurogenetics, Max Planck Institute for Multidisciplinary Sciences, Max Planck Society;

External Resource

There are no locators available

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

フルテキスト (公開)

Publisher Version
(出版社版), 12MB

付随資料 (公開)

There is no public supplementary material available

引用

Chatterjee, M., Özdemir, S., Fritz, C., Möbius, W., Kleineidam, L., Mandelkow, E., Biernat, J., Doğdu, C., Peters, O., Cosma, N., Wang, X., Schneider, L.-S., Priller, J., Spruth, E., Kühn, A., Krause, P., Klockgether, T., Vogt, I., Kimmich, O., Spottke, A., Hoffmann, D., Fliessbach, K., Miklitz, C., McCormick, C., Weydt, P., Falkenburger, B., Brandt, M., Guenther, R., Dinter, E., Wiltfang, J., Hansen, N., Bähr, M., Zerr, I., Flöel, A., Nestor, P., Düzel, E., Glanz, W., Incesoy, E., Bürger, K., Janowitz, D., Perneczky, R., Rauchmann, B., Hopfner, F., Wagemann, O., Levin, J., Teipel, S., Kilimann, I., Goerss, D., Prudlo, J., Gasser, T., Brockmann, K., Mengel, D., Zimmermann, M., Synofzik, M., Wilke, C., Selma-González, J., Turon-Sans, J., Santos-Santos, M., Alcolea, D., Rubio-Guerra, S., Fortea, J., Carbayo, Á., Lleó, A., Rojas-García, R., Illán-Gala, I., Wagner, M., Frommann, I., Roeske, S., Bertram, L., Heneka, M., Brosseron, F., Ramirez, A., Schmid, M., Beschorner, R., Halle, A., Herms, J., Neumann, M., Barthélemy, N., Bateman, R., Rizzu, P., Heutink, P., Dols-Icardo, O., Höglinger, G., Hermann, A., & Schneider, A. (2024). Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS. Nature Medicine, 30(6), 1771-1783. doi:10.1038/s41591-024-02937-4.

引用: https://hdl.handle.net/21.11116/0000-000F-7906-3

要旨

Minimally invasive biomarkers are urgently needed to detect molecular pathology in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). Here, we show that plasma extracellular vesicles (EVs) contain quantifiable amounts of TDP-43 and full-length tau, which allow the quantification of 3-repeat (3R) and 4-repeat (4R) tau isoforms. Plasma EV TDP-43 levels and EV 3R/4R tau ratios were determined in a cohort of 704 patients, including 37 genetically and 31 neuropathologically proven cases. Diagnostic groups comprised patients with TDP-43 proteinopathy ALS, 4R tauopathy progressive supranuclear palsy, behavior variant FTD (bvFTD) as a group with either tau or TDP-43 pathology, and healthy controls. EV tau ratios were low in progressive supranuclear palsy and high in bvFTD with tau pathology. EV TDP-43 levels were high in ALS and in bvFTD with TDP-43 pathology. Both markers discriminated between the diagnostic groups with area under the curve values >0.9, and between TDP-43 and tau pathology in bvFTD. Both markers strongly correlated with neurodegeneration, and clinical and neuropsychological markers of disease severity. Findings were replicated in an independent validation cohort of 292 patients including 34 genetically confirmed cases. Taken together, the combination of EV TDP-43 levels and EV 3R/4R tau ratios may aid the molecular diagnosis of FTD, FTD spectrum disorders and ALS, providing a potential biomarker to monitor disease progression and target engagement in clinical trials.